May 1 (Reuters) - Ampliphi Biosciences Corp APHB.A
* Ampliphi Biosciences Corp - Ampliphi had cash and cash equivalents of $2.2 million as of March 31, 2017
* Ampliphi Biosciences Corp - filed its Australian tax return and now expects receipt of a $1.8 million tax incentive payment early in Q3 of 2017
* Ampliphi Biosciences Corp - has made operational changes that are expected to reduce cash expenditures in 2017
* Ampliphi - expects to provide personalized phage therapies to patients suffering from multidrug-resistant infections who have failed prior therapies
* Ampliphi Biosciences - also seeking to advance chronic rhinosinusitis, preclinical cystic fibrosis programs through partnerships, non-dilutive funding Source text for Eikon: ID:nBw8jfJ24a Further company coverage: APHB.A